BridgeMD
New treatment option for Post Traumatic Stress Disorder
Official title Building Resilience at Schools: Emotional and Biological Assessment and Treatment of Traumatic Stress
ClinicalTrials.gov ID: NCT05701111
What this study is testing
What is iSWAB-DNA?
iSWAB-DNA is an investigational medicine, being studied as a potential treatment for post traumatic stress disorder.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- In the last four years alone, residents of Puerto Rico have experienced a slew of natural disasters including Hurricane Maria in 2017, earthquakes in 2019 and 2020, the continued COVID-19 pandemic from 2020-2022, and most recently Hurricane Fiona. This series of distressing events can lead to an increased need for mental health resources and trauma treatment.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 11 to 17. Healthy volunteers may be eligible.
You may be able to join if
- Teachers and students at a participating school site, Adults and students/caregivers willing to participate in the study
- For Cue Centered Therapy:
- Youth aged 11-17 with exposure to at least one Diagnostic Statistical Manual (DSM) 5-defined traumatic event and meeting threshold criteria for...
- Willingness to participate in therapy
- Caregiver willing to participate in therapy
You likely can't join if
- 1\. For the general study and for Cue Centered Therapy:
- Students doing current trauma-focused interventions with a mental health professional
- Low cognitive functioning (IQ less than 70)
- Substance dependence as defined by DSM criteria
- Autism/Schizophrenia
- Clinically significant medical illness
See the full eligibility criteria
- Teachers and students at a participating school site, Adults and students/caregivers willing to participate in the study
- For Cue Centered Therapy:
- Youth aged 11-17 with exposure to at least one Diagnostic Statistical Manual (DSM) 5-defined traumatic event and meeting threshold criteria for posttraumatic symptoms per the University of California Los Angeles (UCLA)...
- Willingness to participate in therapy
- Caregiver willing to participate in therapy
- Perpetrator of the traumatic event is not living in the home with the child
- 1\. For the general study and for Cue Centered Therapy:
- Students doing current trauma-focused interventions with a mental health professional
- Low cognitive functioning (IQ less than 70)
- Substance dependence as defined by DSM criteria
- Autism/Schizophrenia
- Clinically significant medical illness
The study team makes the final eligibility decision.
Where it's taking place
- Palo Alto, California, United States
- San Juan, Puerto Rico, Puerto Rico
- San Juan, Puerto Rico
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 11 years to 17 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Palo Alto, California, United States; San Juan, Puerto Rico, Puerto Rico; San Juan, Puerto Rico. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.